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Abstract
Ventilator-associated pneumonia (VAP) remains one of the major causes of infection in the intensive care unit (ICU) and is as-
sociated with the length of hospital stay, duration of mechanical ventilation, and use of broad-spectrum antibiotics. We compared 
the frequency of VAP 10 months prior to (pre-intervention group) and 13 months after (post-intervention group) initiation of the 
use of a heat and moisture exchanger (HME) filter. This is a study with prospective before-and-after design performed in the ICU 
in a tertiary university hospital. Three hundred and fourteen patients were admitted to the ICU under mechanical ventilation, 168 
of whom were included in group HH (heated humidifier) and 146 in group HME. The frequency of VAP per 1000 ventilator-days 
was similar for both the HH and HME groups (18.7 vs 17.4, respectively; P = 0.97). Duration of mechanical ventilation (11 vs 12 
days, respectively; P = 0.48) and length of ICU stay (11 vs 12 days, respectively; P = 0.39) did not differ between the HH and 
HME groups. The chance of developing VAP was higher in patients with a longer ICU stay and longer duration of mechanical 
ventilation. This finding was similar when adjusted for the use of HME. The use of HME in intensive care did not reduce the 
incidence of VAP, the duration of mechanical ventilation, or the length of stay in the ICU in the study population.
Key words: Heat and moisture exchanger; Ventilator-associated pneumonia; Quality improvement; Nosocomial infection; 
Critically ill patients 
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Hospital-acquired pneumonia remains as one of the 
main causes of infection in the intensive care unit (ICU) (1,2) 
and is associated with the length of hospital stay (1,3), dura-
tion of mechanical ventilation, and use of broad-spectrum 
antibiotics. This condition results in increased hospital costs 
(1,2,4-6) and patient mortality (3,6). This type of pneumonia 
occurs more frequently in patients who have been on me-
chanical ventilation for more than 48 h, characterizing the 
ventilator-associated pneumonia (VAP). The mortality due 
to VAP varies between 24 and 50%, reaching 76% in high-
risk situations (7). Diagnosis is based on the appearance 
of a new or progressive pulmonary infiltrate accompanied 
by fever, leukocytosis, and purulent sputum (8).
The natural mechanisms of inspired air humidification 
and heating are suppressed during mechanical ventilation. 
Induced air heating and humidification can be achieved 
actively by using heated humidifiers (HH), or passively, by 
means of heat and moisture exchangers (HME). Aspiration 
of the condensed water that is formed in the ventilator circuit 
as a consequence of air heating and humidification is one 
of the causes of VAP. The bacteria colonizing the patients 
themselves can proliferate in the condensate and return to 
the airways and lungs by inhalation of this contaminated 
material. Therefore, it is possible that the use of HME could 
contribute to preventing the onset of VAP with a positive 
impact on the reduction of the incidence of VAP. Various 
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controlled and randomized clinical studies have compared 
HME and HH with respect to the occurrence of VAP (9-12). 
However, data on their real benefit regarding VAP preven-
tion remain inconclusive. 
Data collected in our institution (1999-2009) have re-
vealed an incidence of VAP per 1000 ventilator-days of 18.7 
(Menegueti MG, Bellissimo-Rodrigues F, unpublished data). 
This high incidence has prompted the search for a type of 
intervention that could improve control of this infection. In 
this context, the aim of this study was to evaluate the impact 
of HME on the likelihood of critically ill patients developing 
VAP. The duration of mechanical ventilation, length of ICU 
stay, occurrence of adverse events, and overall mortality 
in the ICU were also investigated. 
Material and Methods
This was a prospective study performed in the ICU of a 
tertiary care hospital associated with a public medical school 
and university. It is a 9-bed adult ICU that delivers intensive 
care to highly complex medical and surgical patients. All 
the patients admitted to the ICU with an expected length 
of stay greater than 48 h were considered eligible for the 
study. The present study was approved by the Research 
Ethics Committee of Hospital das Clínicas, Faculdade de 
Medicina de Ribeirão Preto, Universidade de São Paulo 
(Protocol No. 7076/2010). Written informed consent was 
obtained from all patients or from an appropriate surrogate 
when the patient was unable to provide the consent. This 
investigation consisted of a before-and-after study com-
paring the chance of acquiring VAP 10 months prior to 
(pre-intervention group) and 13 months (post-intervention 
group) after initiation of the use of an HME filter.
Study population 
The study was conducted on 314 patients admitted to 
the ICU under mechanical ventilation, 168 of whom were 
included in group HH and 146 in group HME. Demographic 
and clinical data were collected from the medical records 
and physical examination of the patients. Organ dysfunc-
tion was assessed by Acute Physiology and Chronic Health 
Evaluation (APACHE) II score (13). All patients aged >18 
years submitted to mechanical ventilation and admitted to 
the ICU between January 2009 and November 2010 were 
invited for inclusion in the study and were examined on a 
daily basis. 
The HME hygroscopic filter device (Humid Vent® Filter 
Compact, Gibeck, Germany) was used for all the patients 
undergoing mechanical ventilation and admitted to the 
ICU, provided that there was no contraindication. The de-
vice was changed every 24 h according to manufacturer 
recommendations and the hospital guidelines for infection 
control. Patients were excluded from the study if they 
presented abundant thick secretion with or without blood, 
pulmonary hyperinflation, bulky bronchopleural fistula, body 
temperature lower than 32°C, minute volume >10 L/min, 
low respiratory muscle reserve, or significant impairment 
of the respiratory mechanics due to severe obstruction of 
the airways or acute respiratory distress syndrome and 
bronchospasm. 
The HH was an MR410 Respiratory Humidifier (Fisher 
& Paykel Healthcare Ltd., New Zealand). The ventilators 
consisted of microprocessed equipment (Savina or Evita 
XL, Drägermedical, USA, or Bird 8400, Tri-Bird Prod. Co., 
USA) operating in the mode consistent with the patient’s 
underlying disease.
Identical measures for VAP prevention were established 
for both patient groups: no routine change of ventilator cir-
cuits, a semirecumbent body position, continuous enteral 
nutrition, oral wash with 2% clorhexidine (14,15), respiratory 
physiotherapy, no verification of residual gastric volume, 
and no aspiration of subglottic secretions. 
Daily visits were performed by the ICU staff accompanied 
by a member of the local committee for hospital infection 
control, with the purpose of establishing the VAP diagnosis 
and searching for any adverse events caused by hyper-
capnia and/or endotracheal tube obstruction by secretion. 
These procedures applied for VAP prevention as well as 
the antibiotics policy were under the responsibility of the 
same ICU staff and the hospital infection control members 
for both groups of patients. The diagnosis of pneumonia 
was based on the criteria of the Centers for Disease Control 
and Prevention (16). Pneumonia was considered to be VAP 
when it was diagnosed after 48 h of mechanical ventilation. 
Based on the time of onset of pneumonia, VAP can be fur-
ther categorized into early (occurring within the first 4 days 
of mechanical ventilation) and late (occurring after day 4). 
Etiologically, late VAP is more frequently due to multidrug-
resistant pathogens and has a poorer prognosis than early 
VAP. In general, risk factors are the same (9).
The primary end point was to compare the VAP rate 
between the two groups. Secondary outcomes included 
duration of mechanical ventilation, length of ICU stay, oc-
currence of adverse events, and ICU overall mortality. 
Statistical analysis
From 1999 to 2009, the VAP rate at the study ICU was 
18.7 episodes per 1000 ventilator-days (Menegueti MG, 
Belissimo-Rodrigues F, unpublished data). In order to 
achieve the sufficient power to detect a 60% reduction in 
VAP incidence, with α = 5% and β = 20%, the calculated 
sample size was 125 patients in each group. Considering 
the possible patient’s drop out during the study, the sample 
size was increased to 168 in the HH group and to 146 in the 
HME group. Statistical analyses were performed using the 
SAS 9.2 program (SAS Institute Inc., SAS/STAT® User’s 
Guide, Version 9.2, USA: SAS Institute Inc., 2008). Data 
are reported as median and range and were compared by 
the Mann-Whitney U-test. A P value lower than 0.05 was 
considered to be significant. A post hoc subgroup analysis 
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was conducted by adjusting multiple logistic regression 
models with VAP as the dependent variable and age, 
gender, comorbidities, length of ICU stay, and duration of 
mechanical ventilation as independent variables. 
Results
Of the 325 patients initially included, 11 (3.4%) were 
ultimately excluded because the study protocol was not 
followed correctly (5 patients in the HH group and 6 in the 
HME group).
Overall, 314 patients participated in this investigation. 
They were divided into two groups, namely group HH 
(N = 168), which included patients that utilized HH, and 
group HME (N = 146), which consisted of patients that 
used HME. 
Analysis of the clinical characteristics of the patients 
revealed that both groups had similar distribution in terms of 
age, gender, comorbidity, medical conditions that led to ICU 
admission, and APACHE II score, as summarized in Table 
1. Respiratory failure, risk factors for developing VAP, and 
circulatory shock were also similar for the two groups. 
During the study, 56 VAP events were diagnosed, 29 in 
the HH group (15 early VAP events) and 27 in the HME group 
(18 early VAP events). There were no reductions in VAP rates 
when groups HH and HME were compared. Moreover, the 
incidence of VAP per 1000 ventilator-days was similar in the 
HH and HME groups (18.7 vs 17.4; P = 0.97). There were no 
significant reductions in the incidence of VAP (either early or late 
VAP episodes) in the patients included in the HME group.
Most VAP episodes diagnosed [(43/56 (77%)] were 
confirmed microbiologically, including 21 episodes in the 
HH group and 23 in the HME group. The microorganisms 
isolated are listed in Table 2.
Table 2. Microorganisms isolated from patients with VAP who received heated humidifiers (HH) or heat and moisture exchangers (HME).
Microorganisms HH group HME group
Blood culture Tracheal aspirate or bronchoscopy Blood culture
Tracheal aspirate or 
bronchoscopy
Enterococcus faecalis 1 - - -
Coagulase-negative Staphylococcus 2 - 2 -
Staphylococcus aureus 2 - 1 1
Acinetobacter baumannii 1 7 2 9
Corynebacterium - - 1 1
Enterobacter cloacae 1 - - -
Klebsiella pneumoniae - - - 1
Pseudomonas aeruginosa 2 6 2 5
Serratia marcescens - 1 - -
Stenotrophomonas maltophilia - 1 - 2
Fungus - 2 - 1
Total 9 17 8 20
Data are reported as number of positive results. VAP = ventilator-associated pneumonia.
Table 1. Demographic and clinical characteristics of the patients 
in the HH and HME groups.
HH group 
(N = 168)
HME group 
(N = 146)
Characteristics
Gender (female) 73 (43%) 65 (44%)
Age (mean and range in years) 56 (15-89) 52 (17-87)
APACHE II score (mean and range) 26 (10-47) 27 (10-48)
Death risk (mean and range in %) 56 (6-98) 58 (4-98)
Comorbidity 
Diabetes mellitus 21 (12%) 22 (15%)
Renal failure 35 (21%) 47 (32%)
Coronary disease 34 (20%) 16 (11%)
COPD 15 (9%) 3 (2%)
Infectious diseases 88 (52%) 75 (51%)
Hypertension 52 (31%) 38 (26%)
Malignancy 48 (28%) 34 (23%)
Reason for ICU admission 
Respiratory failure 37 (22%) 25 (17%)
Liver transplantation 9 (5%) 10 (7%)
Major surgery, postoperative 10 (6%) 4 (3%)
Shock 67 (40%) 61 (42%)
Severe sepsis 10 (6%) 18 (12%)
Cardiac arrest 17 (10%) 12 (8%)
Others 18 (11%) 16 (11%)
Risk factor during ICU stay 
Tracheostomy 59 (35%) 59 (40%)
Inhibitors of gastric acid secretion 67 (40%) 61 (42%)
Data are reported as number of patients with percent in paren-
theses or as otherwise stated. HH = heated humidifier group; 
HME = heat and moisture exchanger group; COPD = chronic 
obstructive pulmonary disease. 
1298 M. Auxiliadora-Martins et al.
www.bjournal.com.brBraz J Med Biol Res 45(12) 2012
Duration of mechanical ventilation (11 vs 12 days; P = 
0.48) and length of ICU stay (11 vs 12 days; P = 0.39) did 
not differ between the HH and HME groups. The ICU overall 
mortality was similar for both groups (55.3 vs 55.4%), and 
the death risk calculated by the APACHE II prognostic index 
was 56 and 58% for the HH and HME groups, respectively. 
No adverse event was identified in either group.
The chance of developing VAP did not differ between the 
study groups, thereby demonstrating the ineffectiveness of 
HME as a preventive measure, with a crude odds ratio of 
1.09 (95%CI = 0.61-1.94). After adjustment for gender, age, 
comorbidities, duration of mechanical ventilation, and length 
of stay in the ICU, the likelihood of developing VAP again 
did not differ between the study groups, with an adjusted 
odds ratio of 1.08 (95%CI = 0.57-2.06; Table 3).
Our results also showed that there were no differences 
between groups with respect to duration of mechanical ven-
tilation and length of stay in the ICU after adjustment for HH 
and HME. As for the number of days that patients were kept 
under mechanical ventilation, the chances of developing 
VAP was about five (OR = 5.2; 95%CI = 2.68-10.12), eight 
(OR = 8.43; 95%CI = 2.6-27.33), and eleven (OR = 11.25; 
95%IC = 2.1-60.35) times higher in patients submitted to 
mechanical ventilation for 11-30, 31-50, and over 50 days 
compared to individuals who remained under mechanical 
ventilation for less than 11 days. This result was the same 
after adjustment for utilization of a filter, as shown in Table 
4. Regarding the length of stay in the ICU, the probability 
of developing VAP was about six (OR = 5.92; 95%CI = 
2.99-11.74), eight (OR = 8.38; 95%CI = 2.61-26.94), and 
twelve (OR = 12.57; 95%CI = 2.32-68.15) times higher for 
patients staying for 11-30, 31-50, and over 50 days in the 
ICU compared to those who stayed for less than 11 days. 
These data were also the same after adjustment for filter 
utilization. 
Discussion
Literature studies have been contradictory in relation to 
the impact of HME on VAP prevention. A meta-analysis (9) 
including nine studies and 1378 patients revealed that the 
use of HME reduces VAP rates particularly in individuals 
submitted to mechanical ventilation for over 7 days (relative 
risk = 0.7; 95%CI = 0.50-0.94). However, previous non-
randomized investigations that were not included in this 
meta-analysis had found significantly lower VAP rates 
with the use of HH compared to HME (17,18). Two other 
randomized studies reported a nonsignificant difference in 
VAP rates (10,11), and a randomized investigation includ-
ing 120 patients described a lower VAP incidence with HH 
in patients under mechanical ventilation for over 5 days 
(15.69 vs 39.62%; P = 0.006) (19). A later meta-analysis 
published by Siempos et al. (12), including 13 randomized 
clinical assays representing 2580 patients, did not detect 
any differences between HME and HH in terms of VAP 
incidence, mortality in the ICU, length of stay in the ICU, 
duration of mechanical ventilation, or episodes of airway 
obstruction. 
Table 3. Chances of developing VAP in patients who received heated humidifiers (HH) or heat and 
moisture exchangers (HME).
 VAP No VAP OR crude (95%CI) OR adjusted (95%CI)
HH 29 (9.24) 139 (44.27) 1 1
HME 27 (8.60) 119 (37.90) 1.09 (0.61-1.94) 1.08 (0.57-2.06)
Data are reported as number of VAP cases with percent in parentheses. VAP = ventilator-associated 
pneumonia. OR crude = comparison between groups. OR adjusted = comparison between groups 
adjusted for gender, age, chronic diseases, length of stay, and duration of mechanical ventilation.
Table 4. Duration of mechanical ventilation in the study population.
Mechanical ventilation (days) VAP No VAP OR crude (95%CI) OR adjusted (95%CI)
Up to 10 16 (5.10) 180 (57.32) 1 1
11 to 30 31 (9.87) 67 (21.34) 5.20 (2.68-10.12) 5.21 (2.68-10.14)
31 to 50 6 (1.91) 8 (2.55) 8.43 (2.6-27.33) 8.32 (2.56-27.09)
>50 3 (0.96) 3 (0.96) 11.25 (2.1-60.35) 11.37 (2.11-61.19)
Data are reported as number of VAP cases with percent in parentheses. VAP = ventilator-associated 
pneumonia. OR crude = comparison between groups. OR adjusted = comparison between groups 
adjusted for gender, age, chronic diseases and length of stay.
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Our data indicate that the use of HME was not enough 
to prevent VAP in ICU patients. This is corroborated by 
the fact that there were no differences between the study 
groups for any of the parameters evaluated, including 
VAP incidence, duration of mechanical ventilation, length 
of stay in the ICU, and global mortality rate. On the other 
hand, filter utilization led to optimization of the work of 
the nursing staff since application of the filter eliminated 
the need to open the circuit and discard the water that 
accumulated in the respirator. There was also a fall in the 
number of technical problems with the respirator sensors, 
which contributed to reduced expenditure with maintenance 
services. Regarding HME expenses in our institution, the 
average daily cost per patient was US$6.48 vs US$5.9 for 
HH and HME, respectively. Despite the lower HME cost, 
also demonstrated in other studies (10), it is noteworthy 
that this device is not exempt from risks. The most severe 
complication is endotracheal tube obstruction by secretion. 
This is due to diminished moisture production, especially 
when a larger minute volume is employed, which is com-
mon to all commercially available instruments to a higher 
or lesser extent (17,20). In our case, obstruction of the 
endotracheal tube with need for re-intubation did not occur, 
but this is an adverse effect that has been described in other 
studies (21-28). Another concern is the increase in dead 
space with hypercapnia and airway resistance, which are 
mainly dependent on the internal volume of the filter and 
accumulation of liquids, respectively (29-31). In the pres-
ent study, there was no record of hypercapnia or increased 
airway resistance requiring HME withdrawal. 
Here, the fact that there was no reduction in the rate of 
VAP in the presence of HME compared to HH is in agree-
ment with various published randomized investigations 
(10-12,17-19). A study by Kirton et al. (21) evaluating 280 
trauma victims reported a lower VAP incidence for HME. A 
possible explanation for the fact that our results were differ-
ent from those of Kirton et al. would be the severity of the 
patients (APACHE II >25) included herein associated with 
their several comorbidities. Other aspects that could influ-
ence our results refer to the filters employed in the present 
investigation, which were provided by different suppliers 
from those of other studies, as well as the frequency of filter 
exchange and the diagnostic criteria for VAP. Moreover, the 
studied populations differed between investigations (21). 
Nevertheless, various clinical studies have demonstrated 
that longer HME use, from 24-48 h up to 4 or 7 days, is not 
related to an increased risk of VAP (32-34). 
Our results agree with the proposed VAP pathophysiol-
ogy in the sense that inoculation of bacteria into the lungs is 
believed to usually occur through the extraluminal source, 
while it is thought to take place by the intraluminal route 
only sporadically (35,36).
The present study has some limitations. First, direct as-
sessment of the heating and humidification of the inspired 
air was not carried out, since we relied on manufacturer 
specifications. Secondly, VAP was not diagnosed via an 
invasive procedure for all patients; in some individuals, only 
clinical and radiological criteria were employed for diagnosis. 
Finally, our study did not include a randomized trial. 
It may be suggested that both HH and HME can be 
utilized in the ICU, without any significant impact on VAP 
incidence. Considering hospital costs and lack of contrain-
dications, the use of HME should be considered as an 
alternative humidification method for patients submitted 
to mechanical ventilation. Further studies are necessary 
for clarification of the actual effect of this device on VAP 
prevention. 
Our results have demonstrated that the use of HME in 
an intensive care unit did not reduce the incidence of VAP, 
the duration of mechanical ventilation, or the length of stay 
in the ICU in the study population.
Acknowledgments 
We are thankful to Davi Casale Aragon for assistance 
with the statistical analysis. Research supported by Fun-
dação de Amparo ao Ensino, Pesquisa e Assistência (FA-
EPA), Hospital das Clínicas and Faculdade de Medicina 
de Ribeirão Preto-USP. 
References
 1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, 
Nicolas-Chanoin MH, et al. The prevalence of nosocomial 
infection in intensive care units in Europe. Results of the 
European Prevalence of Infection in Intensive Care (EPIC) 
Study. EPIC International Advisory Committee. JAMA 1995; 
274: 639-644.
 2. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, 
Redman R, et al. Epidemiology and outcomes of ventilator-
associated pneumonia in a large US database. Chest 2002; 
122: 2115-2121.
 3. Bercault N, Boulain T. Mortality rate attributable to ventilator-
associated nosocomial pneumonia in an adult intensive care 
unit: a prospective case-control study. Crit Care Med 2001; 
29: 2303-2309.
 4. Chen YY, Wang FD, Liu CY, Chou P. Incidence rate and 
variable cost of nosocomial infections in different types of 
intensive care units. Infect Control Hosp Epidemiol 2009; 
30: 39-46.
 5. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollen-
beak CS, Cox MJ, et al. Outcome and attributable cost of 
ventilator-associated pneumonia among intensive care unit 
patients in a suburban medical center. Crit Care Med 2003; 
31: 1312-1317.
 6. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and eco-
1300 M. Auxiliadora-Martins et al.
www.bjournal.com.brBraz J Med Biol Res 45(12) 2012
nomic consequences of ventilator-associated pneumonia: a 
systematic review. Crit Care Med 2005; 33: 2184-2193.
 7. Meduri GU. Diagnosis and differential diagnosis of ventilator-
associated pneumonia. Clin Chest Med 1995; 16: 61-93.
 8. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander 
D, et al. International Conference for the Development of 
Consensus on the Diagnosis and Treatment of Ventilator-
Associated Pneumonia. Chest 2001; 120: 955-970.
 9. Kola A, Eckmanns T, Gastmeier P. Efficacy of heat and 
moisture exchangers in preventing ventilator-associated 
pneumonia: meta-analysis of randomized controlled trials. 
Intensive Care Med 2005; 31: 5-11.
10. Lacherade JC, Auburtin M, Cerf C, Van de Louw A, Soufir 
L, Rebufat Y, et al. Impact of humidification systems on 
ventilator-associated pneumonia: a randomized multicenter 
trial. Am J Respir Crit Care Med 2005; 172: 1276-1282.
11. Boots RJ, George N, Faoagali JL, Druery J, Dean K, Heller 
RF. Double-heater-wire circuits and heat-and-moisture ex-
changers and the risk of ventilator-associated pneumonia. 
Crit Care Med 2006; 34: 687-693.
12. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Impact 
of passive humidification on clinical outcomes of mechani-
cally ventilated patients: a meta-analysis of randomized 
controlled trials. Crit Care Med 2007; 35: 2843-2851.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 
APACHE II: a severity of disease classification system. Crit 
Care Med 1985; 13: 818-829.
14. Bellissimo-Rodrigues F, Bellissimo-Rodrigues WT, Viana JM, 
Teixeira GC, Nicolini E, Auxiliadora-Martins M, et al. Effective-
ness of oral rinse with chlorhexidine in preventing nosocomial 
respiratory tract infections among intensive care unit patients. 
Infect Control Hosp Epidemiol 2009; 30: 952-958.
15. Koeman M, van der Ven AJ, Hak E, Joore HC, Kaasjager K, 
de Smet AG, et al. Oral decontamination with chlorhexidine 
reduces the incidence of ventilator-associated pneumonia. 
Am J Respir Crit Care Med 2006; 173: 1348-1355.
16. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. 
Guidelines for preventing health-care-associated pneumo-
nia, 2003: recommendations of CDC and the Healthcare 
Infection Control Practices Advisory Committee. MMWR 
Recomm Rep 2004; 53: 1-36.
17. Cohen IL, Fein IA. Norepinephrine therapy in septic shock. 
Crit Care Med 1988; 16: 206-207.
18. Blin F, Fraisse F, Chauveau P, Lahilaire P, Boulet E, Bou-
haddi R, et al. Incidence of nosocomial pneumonias among 
1788 ventilated patients in 6 ICU according to the type of 
humidification used. Intensive Care Med 1996; 22: S324.
19. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A. 
Ventilator-associated pneumonia using a heated humidifier 
or a heat and moisture exchanger: a randomized controlled 
trial [ISRCTN88724583]. Crit Care 2006; 10: R116.
20. Doyle A, Joshi M, Frank P, Craven T, Moondi P, Young P. A 
change in humidification system can eliminate endotracheal 
tube occlusion. J Crit Care 2011; 26: 637 e1-4.
21. Kirton OC, DeHaven B, Morgan J, Morejon O, Civetta J. 
A prospective, randomized comparison of an in-line heat 
moisture exchange filter and heated wire humidifiers: rates 
of ventilator-associated early-onset (community-acquired) or 
late-onset (hospital-acquired) pneumonia and incidence of 
endotracheal tube occlusion. Chest 1997; 112: 1055-1059.
22. Martin C, Perrin G, Gevaudan MJ, Saux P, Gouin F. Heat 
and moisture exchangers and vaporizing humidifiers in the 
intensive care unit. Chest 1990; 97: 144-149.
23. Roustan JP, Kienlen J, Aubas P, Aubas S, du Cailar J. Com-
parison of hydrophobic heat and moisture exchangers with 
heated humidifier during prolonged mechanical ventilation. 
Intensive Care Med 1992; 18: 97-100.
24. Dreyfuss D, Djedaini K, Gros I, Mier L, Le Bourdelles G, 
Cohen Y, et al. Mechanical ventilation with heated humidi-
fiers or heat and moisture exchangers: effects on patient 
colonization and incidence of nosocomial pneumonia. Am J 
Respir Crit Care Med 1995; 151: 986-992.
25. Boots RJ, Howe S, George N, Harris FM, Faoagali J. Clinical 
utility of hygroscopic heat and moisture exchangers in inten-
sive care patients. Crit Care Med 1997; 25: 1707-1712.
26. Hurni JM, Feihl F, Lazor R, Leuenberger P, Perret C. Safety 
of combined heat and moisture exchanger filters in long-term 
mechanical ventilation. Chest 1997; 111: 686-691.
27. Kollef MH, Shapiro SD, Boyd V, Silver P, Von Harz B, 
Trovillion E, et al. A randomized clinical trial comparing an 
extended-use hygroscopic condenser humidifier with 
heated-water humidification in mechanically ventilated pa-
tients. Chest 1998; 113: 759-767.
28. Memish ZA, Oni GA, Djazmati W, Cunningham G, Mah MW. 
A randomized clinical trial to compare the effects of a heat 
and moisture exchanger with a heated humidifying system 
on the occurrence rate of ventilator-associated pneumonia. 
Am J Infect Control 2001; 29: 301-305.
29. Briassoulis G, Paraschou D, Hatzis T. Hypercapnia due to 
a heat and moisture exchanger. Intensive Care Med 2000; 
26: 147.
30. Wilkes AR. Heat and moisture exchangers and breathing 
system filters: their use in anaesthesia and intensive care. 
Part 1 - history, principles and efficiency. Anaesthesia 2011; 
66: 31-39.
31. Wilkes AR. Heat and moisture exchangers and breathing 
system filters: their use in anaesthesia and intensive care. 
Part 2 - practical use, including problems, and their use with 
paediatric patients. Anaesthesia 2011; 66: 40-51.
32. Markowicz P, Ricard JD, Dreyfuss D, Mier L, Brun P, Coste F, 
et al. Safety, efficacy, and cost-effectiveness of mechanical 
ventilation with humidifying filters changed every 48 hours: 
a prospective, randomized study. Crit Care Med 2000; 28: 
665-671.
33. Thomachot L, Boisson C, Arnaud S, Michelet P, Cambon S, 
Martin C. Changing heat and moisture exchangers after 96 
hours rather than after 24 hours: a clinical and microbiologi-
cal evaluation. Crit Care Med 2000; 28: 714-720.
34. Thomachot L, Leone M, Razzouk K, Antonini F, Vialet R, 
Martin C. Randomized clinical trial of extended use of a 
hydrophobic condenser humidifier: 1 vs. 7 days. Crit Care 
Med 2002; 30: 232-237.
35. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ven-
tilator-associated pneumonia: its relevance to developing 
effective strategies for prevention. Respir Care 2005; 50: 
725-739.
36. Cardenosa Cendrero JA, Sole-Violan J, Bordes BA, Noguera 
CJ, Arroyo FJ, Saavedra SP, et al. Role of different routes of tra-
cheal colonization in the development of pneumonia in patients 
receiving mechanical ventilation. Chest 1999; 116: 462-470.
